247 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
to relevant governmental authorities the payments made by or on behalf of the Company to Consultant under this Agreement, as well as the purpose and nature … concerning Consultant, and any other information relating to this Agreement.
7. Confidentiality of Proprietary Information.
(a) Nature of Information
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
or representations to the contrary are superseded by this Agreement. The at-will nature of the Executive’s employment may be changed only in an express, written
8-K
EX-10.1
ftc65 xba8gq8efb4f
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
8-K
EX-10.1
hdsm4xwfkxo8zcu 86
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
8-K
EX-10.2
qzqadh zm5bpk
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
8-K
EX-10.1
t4gcn7f3 vn59rgmiy3s
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
424B5
1ih29
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
0hp5q 01ohqqbppfo8
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-10.1
t7r8js0
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
CORRESP
8py60kpjte9
7 Jul 23
Correspondence with SEC
12:00am
UPLOAD
vcmy7a
28 Jun 23
Letter from SEC
12:00am
8-K
EX-10.1
vu5ozi5y7n avmxi
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm